Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-
1) infection has reached pandemic proportions. Forty years later, research has led to the …

The human immunodeficiency virus (HIV) is responsible for acquired immune deficiency
syndrome (AIDS), one of the major pandemic diseases. Highly active antiretroviral therapy …

Currently, HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a major
component of the highly active anti-retroviral therapy (HAART) regimen. However, the …

HIV reverse transcriptase (RT) inhibitors are the important components of highly active
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …

During HIV-1 genome replication, the viral reverse transcriptase-associated ribonuclease H
(RT-associated RNase H) activity hydrolyzes the RNA strand of RNA/DNA heteroduplex …

Advances in biotechnology have led to improving human health with number of novel
approaches to mitigate life-threatening diseases such as human immunodeficiency virus …

ABSTRACT Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor (NNRTI),
was approved for treatment of HIV-1 infection in 2018. In the pivotal phase 3 trials, DRIVE …

To thoroughly investigate the uncharted chemical space around the entrance channel of HIV-
1 reverse transcriptase (RT) and to improve the physicochemical properties, we introduced …

Doravirine is a well tolerated and effective agent in ART-naive patients. Direct comparison
with integrase inhibitors, and evidence on the outcomes of treatment with doravirine in the …

Human immunodeficiency virus (HIV)-infected individuals display an enhanced production
of reactive oxygen species (ROS). This reduction of antioxidant capacity in host tissues has …